Trevi Therapeutics, Inc. (TRVI)
NASDAQ: TRVI · Real-Time Price · USD
6.50
-0.03 (-0.38%)
At close: Mar 28, 2025, 4:00 PM
6.45
-0.05 (-0.77%)
After-hours: Mar 28, 2025, 7:27 PM EDT
Trevi Therapeutics Stock Forecast
Stock Price Forecast
The 8 analysts with 12-month price forecasts for Trevi Therapeutics stock have an average target of 17.56, with a low estimate of 7.00 and a high estimate of 29. The average target predicts an increase of 170.15% from the current stock price of 6.50.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Trevi Therapeutics stock from 8 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Oct '24 | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 5 | 5 | 5 | 5 | 6 |
| Buy | 3 | 3 | 3 | 3 | 3 | 2 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 8 | 8 | 8 | 8 | 8 | 8 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| B. Riley Securities | B. Riley Securities | Strong Buy Reiterates $11 → $20 | Strong Buy | Reiterates | $11 → $20 | +207.69% | Mar 19, 2025 |
| Needham | Needham | Strong Buy Maintains $25 → $24 | Strong Buy | Maintains | $25 → $24 | +269.23% | Mar 19, 2025 |
| D. Boral Capital | D. Boral Capital | Strong Buy Maintains $21 | Strong Buy | Maintains | $21 | +223.08% | Mar 19, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $13 | Strong Buy | Reiterates | $13 | +92.31% | Mar 19, 2025 |
| Oppenheimer | Oppenheimer | Buy Maintains $12 → $20 | Buy | Maintains | $12 → $20 | +207.69% | Mar 11, 2025 |
Financial Forecast
Revenue This Year
n/a
from 171.27M
Revenue Next Year
n/a
EPS This Year
-0.53
from -0.47
EPS Next Year
-0.60
from -0.53
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | n/a | n/a | 18.6M | ||
| Avg | n/a | n/a | 3.4M | ||
| Low | n/a | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -0.43 | -0.28 | -0.20 | ||
| Avg | -0.53 | -0.60 | -0.73 | ||
| Low | -0.68 | -0.81 | -1.18 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.